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ABSTRACT 
Background: Socio-economic status (SES) is related to breast cancer diagnosis and 
prognosis. We study if SES of the participants is related to the adequacy of the treatment 
according to Saint Gallen consensus in Spanish women.  
Methods: Breast cancer cohort was assembled from incident cases from MCC-Spain and 
prospective followed-up afterwards. Participants were then classified according to the 
consensus. Association between SES and Saint Gallen fulfillment was analyzed using 
multinomial logistic regression, adjusting for clinicopathological variables.  
Results: 1110 patients in stages I and II were included. Women with university studies 
were twice as likely to receive over Saint-Gallen therapies (RRR = 2.27, 95%CI 1.26 – 
4.09). We observed a 14% increase in the chances of being over Saint-Gallen per point 
of the SES score (RRR per point 1.14, 95%CI 1.03 – 1.25). In the simplified SES score, 
women at higher SES were over Saint-Gallen twice as those at lower SES (RRR 2.12, 
95%CI 1.29 – 3.48). 
Conclusions: Women at higher SES more often received over Saint-Gallen therapies. 
Being at lower SES was not associated with over or under Saint Gallen treatment. 
Further analyses are needed to understand the influence of these differences on the 
overall survival as well as its potential unwanted side effects.  
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RESUMEN 
Introducción: El estado socioeconómico (ESE) está relacionado con el diagnóstico y el 
pronóstico del cáncer de mama. Nuestro objetivo es analizar si el SES de los 
participantes está relacionado con la adecuación del tratamiento según el consenso de 
Saint Gallen en mujeres españolas. 
Métodos: La cohorte de cáncer de mama se formó a partir de casos incidentes de MCC-
España y posteriormente se realizó un seguimiento prospectivo. Los participantes 
fueron clasificados de acuerdo con el consenso. La asociación entre SES y el 
cumplimiento de Saint Gallen se analizó mediante regresión logística multinomial, 
ajustando por variables clínico-patológicas. 
Resultados: Se incluyeron 1110 pacientes en estadios I y II. Las mujeres con estudios 
universitarios tuvieron el doble de probabilidades de recibir terapias que excedían Saint-
Gallen (RRR = 2.27, IC del 95%: 1.26 - 4.09). Observamos un aumento del 14% en las 
posibilidades de estar por encima de Saint-Gallen por punto del score (RRR por punto 
1.14, IC 95% 1.03 - 1.25). En la escala ESE simplificada, las mujeres con un ESE más alto 
fueron tratadas sobre Saint-Gallen dos veces más que las del ESE más bajo (RRR 2,12; IC 
del 95%: 1,29 a 3,48). 
Conclusiones: Las mujeres con un ESE más alto reciben son más frecuentemente 
tratadas con terapias por encima de Saint-Gallen. No se encontró asociación entre ESE 
bajo y ser tratada por debajo de Saint Gallen. Se necesitan análisis posteriores para 
conocer la relación entre este resultado y la supervivencia, así como sus posibles efectos 
secundarios. 
Palabras clave: Cáncer de mama, consenso de Saint-Gallen, estado socioeconómico, 
MCC-Spain.  
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THE INFLUENCE OF SOCIO-ECONOMIC STATUS ON THE 
FULFILLMENT OF SAINT-GALLEN RECOMMENDATIONS 
FOR EARLY-STAGE BREAST CANCER 
1. INTRODUCTION 
Breast cancer is the leading cause of female cancer in Europe, America and Australia. 
(1–5) In Europe is estimated to affect 1 in 10 women, accounting for 28.8% of the total 
of female cancer. (6) Evidence so far indicates that we can classify breast carcinoma 
according to their different histopathological and biological features as they also exhibit 
different behaviors leading to distinct therapeutic strategies. Classical 
immunohistochemistry markers including ER, PR and HER2 together with TNM staging 
are commonly used to clarify patient’s prognosis and future management. (7)  
Saint Gallen International Expert Panel (2013) reviewed substantial new evidence on 
aspects of the local and regional therapies for early breast cancer supporting a less 
aggressive approach, especially for the luminal disease in absence of HER2. Therapies 
for HER2-positive and “triple negative” disease remained almost unchanged. Yet still, 
clinical consideration of extension of the disease, performance status of the patient as 
well as their personal preferences and socioeconomic constraints will play a part in the 
definitive decision of the treatment. (8) In those areas of the world where multi-gene 
molecular assays are available, many clinicians rely on the results to approach decisions 
about adjuvant chemotherapy in the protocols of patients with Luminal ER-positive, 
HER2-negative disease on early stages, without systemic invasion. (9) 
Socio-economic status (SES) has constantly been related to breast cancer diagnosis and 
prognosis for the past years leading to a variety of researches. In general, higher SES has 
been associated with higher incidence of breast cancer. (1,4,5,10,11) Several 
explanations have been proposed such as parity circumstances (1), hormonal 
circumstances including oral contraceptives and hormone replacement  (12), access to 
healthcare, cancer awareness, screening methods (5), lifestyle habits (13) and other 
issues that need to be disclosed in future investigations.  
On the other hand, most studies have shown significantly lower case-fatality rate for 
women with higher SES, probably related to some of the reasons mentioned above, 
women of higher SES are more likely to be diagnosed with a lower stage tumor and also 
they would probably adopt healthier lifestyles after diagnosis, including also a better 
psychological background (1,2,5,10). Other studies have shown that conservative 
surgeries and consecutive follow-ups are more common among women with higher SES 
which could also partly explain their lower case-fatality rate. (14) 
  4 
 
The greater risk of breast cancer mortality among women with a higher level of 
education being these also related to a higher SES was a persistent and extended 
phenomenon in Europe in the 1990s. (15) However, more recent literature about 2000s 
period provides ambiguous information referring to mortality rates. Some studies 
indicate a higher mortality for women with higher SES. Women with higher SES have 
lower parity rate and delay of first birth which increase their breast cancer risk and could 
also lead to worse prognosis. (1) Others demonstrate that breast cancer patients of low 
SES have a significantly increased risk of dying as a result of breast cancer compared to 
the risk in patients of high SES. Low SES patients were diagnosed at a later stage, had 
different tumor characteristics and more often received suboptimal treatment.(5)  
Socio-economic position remains a strong predictor of poor survival for deprived women 
compared with affluent women, even after adjustment for other known prognostic 
factors including age, ethnicity, access to care variables (extent and size) and tumour 
subtype adjusting for ER, PR and HER2.  (4) Over mortality linked to low SES is only partly 
explained by delayed diagnosis (related to screening methods), unfavorable tumor 
characteristics and suboptimal treatments, which creates the need to discover other 
possible explanations. Other reasons linked to the patient’s health, like comorbidity, 
lifestyle, attitude, knowledge and convictions also could play a role. Low SES patients 
are more often in complex psychosocial difficulties which complicate treatments, as 
most effective ones are sometimes linked to certain adverse effects that require a 
particular performance status including psychological support. They are also more likely 
to have misperceptions about cancer and treatment benefits, to miss their medical visits 
and to be less participatory. (14) 
MCC-Spain intends to explore and combine different approaches in order to identify 
new risk factors and provide new data that might help to prevent their occurrence in 
the future. (16) In this paper we will study if socio-economic status of the participants is 
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2. MATERIALS AND METHODS 
MCC-Spain began as a case-control study focused in the most frequent tumors in Spain 
including colorectal, female breast, prostate and gastric cancers and chronic 
lymphocytic leukaemia. This study was developed by the Consortium for Biomedical 
Research in Epidemiology and Public Health (CIBERESP) and carried out in 12 Spanish 
provinces (Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Granada, Huelva, León, 
Madrid, Murcia, Navarra and Valencia). Recruitment began in September 2008 and 
finished in December 2013, calling up 10,183 cases and controls between 20 and 85 
years old who had lived in the catchment area for at least 6 months before the diagnosis 
and who were able to answer an epidemiological questionnaire. The design of this study 
has been published elsewhere (16). 
Later in 2016 the MCC-Spain decided to assemble three different cohorts (colorectal, 
breast and prostate) using incident cases, only if histologically confirmed. They were 
recruited rapidly after diagnosis and placed into their proper cohort; colorectal (2140 
cases), breast (1738 cases) and prostate (1112 cases). Their prospective follow-up has 
been performed between 2017 and 2018 by reviewing medical records. For patients 
whose last contact with the hospital had occurred 3 or more months before our revision 
of her medical record, The National Death Index (Índice Nacional de Defunciones -IND-) 
(17) was consulted to realize their vital status.  
Patients alive at the follow-up were contacted by phone and asked to complete 
questionnaires regarding their quality of life: SF-12 (18) for each cohort and FACT/NCCN 
Breast Symptom Index (19) for breast cancer cohort specifically. From here on, we will 
only be referring to the breast cancer cohort.  
Initial tumor information 
In order to collect information on pathology characteristics and tumour extension, 
medical records of each patient were reviewed by trained personnel. Tumour location, 
differentiation’s degree, immunohistochemical characteristics (hormonal receptors, 
Erb-B2) and TNM status were dug out from each of the patients’ records. During the 
follow-up, information regarding histological grade at diagnosis, complete 
clinical/pathological remission, grade of response to treatment, relapse, second primary 
tumour and current patient’s vital status was also gathered.  
 
Initial first-line treatment information 
For each patient, information about their first-line treatment was also collected from 
their medical records and classified into surgery (conservative /mastectomy), 
hormonotherapy, chemotherapy, immunotherapy and radiotherapy (all of them 
classified into neoadjuvant, adjuvant or palliative administrations).  
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Socio-economic status information  
Socio-Economic Status (SES) was measured by a compendium of variables including: 
Educational Level, Educational Level of the companion, Socio-Economic Position of both 
the patient and the parents and finally Degree of Urbanization and Urban Vulnerability 
Index. There variables were compared individually and also combined as scores.  
Educational level of both the participants and their companions was divided into four 
groups including less than primary, primary, secondary and university studies. Socio-
Economic status of participants’ parents was assorted attending to whether it was low, 
medium or high. Information regarding participants’ longest occupation was also 
gathered and classified (according to the Spanish Occupational Classification) (20) into 
three further groups; low (V), medium (IIIb, IIIc, Iva, IVb) and high (IIIa, II, I).   
In order to build the individual SES score, participants’ education, SES of the parents and 
SOC were combined. Each of the variables score 0 – 3 or 0 – 2 attending its number of 
categories being 0 the lowest level. During the questionnaire, 70 patients did not report 
their occupation and their parents’ economic position; 4 did not report parents’ 
economic position and 298 did not report their occupation. Only those who reported 
the three variables were assembled into a score from 0 – 7 by combining the points 
received in the described categories. Once divided into these categories a simplified SES 
score was created, dividing the participants into three bigger groups including low SES 
(0, 1, 2); medium SES (3, 4, 5) and high SES (6, 7).  For those participants who were 
missing only one of the variables a similar score was created, also classifying them into 
low SES (0,1); medium SES (2, 3) and high SES (4, 5). Participants missing two of them 
were excluded from this score.  
The contextual socioeconomic status was measured by the Urban Vulnerability Index 
(UVI-SE) as published in the Spanish Ministry of Foment(21). It combines five indicators 
based on the proportion of: unemployed, unemployed aged 16 – 29 years old, non-fixed 
employed, employed without qualification and people without studies. The UVI-SE score 
ranges from 0 (lower vulnerability) to 1 (higher vulnerability). Each patient was allocated 
to the UVI-SE of her area of last residence.  
The Degree of urbanization (DGUR) was also used in order to consider participants’ 
residence as a SES indicator.  It is a classification that indicates the character of an area. 
The latest update of the classification is based on 2011 population grid and the 2016 
Local Administrative Units (LAU) boundaries. Based on the share of local population 
living in urban clusters and in urban centers, it classifies them into three types of area: 
Cities (densely populated areas), Towns and suburbs (intermediate density areas), Rural 
areas (thinly populated areas). (22) 
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Classification of the patients according to Saint-Gallen fulfillment  
In order to classify the participants according to Saint-Gallen fulfillment, information 
described above (type of tumour and first line treatment) was used and compared to 
the recommendations given.  
Systematic treatment recommendations agreed by Saint-Gallen consensus were:  
- Luminal A-like: Endocrine therapy is the most critical intervention and is often 
used alone. Cytotoxics may be added in selected patients with high risk profiles.  
- Luminal B-like (HER2 negative): Endocrine therapy for all patients and cytotoxic 
therapy for most.  
- Luminal B-like (HER2 positive): Cytotoxics + anti-HER2 + endocrine therapy 
- HER2 positive (non-luminal): Cytotoxics + anti-HER2 
- Triple negative (ductal): Cytotoxics  
 
Regarding surgery and radiotherapy; the Panel agreed that, in general, conservative 
surgery – only if followed by radiotherapy of the whole breast - was as appropriate a 
mastectomy (except for high risk profiles including young age, microcalcifications, 
BRCA1 o BRCA2 genes, etc). Surgery of the axilla could be omitted only if radiotherapy 
was arranged, but it was required if three or more sentinel nodes were involved or if 
they were clinically involved before surgery and confirmed by biopsy. Radiotherapy was  
an option for almost all the women except for the elderly and those with substantial 
comorbidity. (8) 
When classifying our patients, we payed special attention to systemic therapies as rest 
of the recommendations were somewhat diffuse. Criteria followed were:  
▪ In Saint-Gallen women: participants who received the therapy accorded by Saint 
Gallen. Example: Women with luminal A-like tumour (ER+, PR+, HER2-) who had 
breast conserving surgery, radiotherapy and endocrine therapy.  
▪ Over Saint-Gallen women: participants that, even if they received everything 
they were supposed to, also received some futile therapy. Example: Women with 
basal-like tumour (ER-, PR-, HER2-) who had breast conserving surgery, 
radiotherapy, cytotoxics and endocrine therapy.  
▪ Under Saint-Gallen women: participants that did not received the complete 
therapy that was recommend, even if they received something else. Example: 
Women with HER2 tumour (ER-, PR-, HER2+) who had breast conserving surgery, 
radiotherapy, endocrine therapy and cytotoxics; lacking anti-HER2 therapy.  
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Assorting the participants in these three groups could be considered rather subjective, 
as the consensus provided recommendations and not protocols, and also because 
individual cases might be considered. In order to check our agreement while classifying 
them, two different observers classified a sample of 50 women reaching 76% inter-rater 
concordance. (Cohen’s kappa index = 0.76).  
 
Statistical analysis 
Descriptive Data are described using absolute frequencies and means with standard 
deviation. SES indicators and Saint-Gallen fulfillment were analyzed using Pearson’s chi2 
(one test for each of 5 indicators) and Analysis of Variance for the remaining indicator 
(UVI). 
After adjusting for stage at presentation and histologic grade, the association between 
SES indicators and Saint-Gallen Fulfillment was analyzed using multinomial logistic 
regression including as regressors all seven SES indicators (one logistic regression for 
each regressor). Results are displayed as relative risk ratios with 95% confidence 
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3. RESULTS 
Description of the sample  
Overall, 1110 women with stages I and II at diagnosis were included in the analysis and 
later classified into three groups (In Saint-Gallen, Over Saint-Gallen and Under Saint-
Gallen) according to the fulfilment of Saint-Gallen. Table 1 displays the main 
characteristics of the sample. Most of the women were postmenopausal (65%). 
Compared with the others, over St Gallen women were younger (52.9) and also more 
likely to be premenopausal. Tumour size was predominantly T1 (66%) and it was 
considered in St Gallen twice as often as over St Gallen or under St Gallen respectively 
(57.8% vs 21.2% vs 31%). For T2 (25.5%), the distribution was similar (42.1% vs 27.2% vs 
30.7%).  
In this study we only consider earlier stages including: stage I (57.4%) which are tumours 
smaller than 2.5 cm across and stage II (42.6%) tumour less than 5 cm across which could 
have spread (N1 = 32.9%) or not (N0 = 66.6%) to the axillary lymph nodes. Stage I 
tumours considered in St Gallen accounted 49.8% versus 14.4% of over St Gallen and 
35.8% of under St Gallen. For the stage II tumours the proportions were more 
homogeneous (37.2% vs 32.1% vs 30.7%). 
Regarding the intrinsic subtype, Luminal A was by far the most common tumour (68.4%); 
with a proper fulfilment of Saint-Gallen of 45.4%. Luminal B (19.3%) and Her2 (4.6%) 
tumours were frequently under Saint-Gallen (60.3% and 54.9% respectively). Basal-like 
tumours represent 7.8% of our sample, and they were predominantly in Saint-Gallen 
(74.4% vs 4.7% vs 20.9%). According to grade of differentiation, well differentiated 
accounted for 23% of breast cancers; moderately differentiated accounted 30.3% and 
bad differentiated 19.1%. Grade could not be obtained from medical records in 307 
patients (27.7%). Proportions for Saint-Gallen fulfilment are displayed with detail in 
table 1.  
When considering the treatment specifically, conservative surgery was performed in 
861 participants and mastectomy in the remaining 249 with 72% of negative surgical 
margins. Chemotherapy was administered to 577 patients, 41.9% of them were 
considered over Saint-Gallen while 22% were under Saint-Gallen. From the 747 patients 
that received endocrine therapy only in 55.4% received in Saint-Gallen therapies while 
30.9% were over Saint-Gallen. The remaining 363 did not receive endocrine therapy and 
271 were considered under Saint-Gallen. Finally, immunotherapy was given to 107 
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Factors associated with over Saint-Gallen participants 
In the crude analysis, women of higher educational level had the highest over Saint-
Gallen rate (Table 2). Women with less than primary education were less frequently over 
Saint-Gallen than women with University studies (15.5% vs. 28.2%). When adjusting for 
stage at presentation and histologic grade (Table 3) women, the higher the education, 
the higher the probability of being over Saint-Gallen reaching RRR = 2.27 when 
compared with those in the lower education level (95%CI 1.26 – 4.09). No association 
between Educational Level of the companion and overtreatment of the patients was 
found (Table 2).  
Women of higher SES were more often over Saint-Gallen (Table 2). These differences 
remained in the simplified SES score, High SES 29.9%, Medium SES 21.8% and Low SES 
18.3%. Results adjusted for stage and histology grade (Table 3) showed a 14% increase 
in the chances of being over Saint-Gallen per point of the score (RRR per point 1.14, 
95%CI 1.03 – 1.25). In the simplified SES score (Table 3) the probability for women of 
higher SES of being over Saint-Gallen was twice as those from lower SES (RRR 2.12, 
95%CI 1.29 – 3.48). 
No significative association was found between Saint Gallen fulfillment and SES of the 
parents, Degree of Urbanization (DGUR) or Urban Vulnerability Index (UVI) (Table 3).  
 
 
Factors associated with under Saint-Gallen participants 
The crude analysis showed that women of lower education are more likely to be under 
Saint-Gallen compared to those of higher education (Table 2). Nevertheless, the 
differences were scarce (less than Primary 37.9% and University studies 30.1%) and after 
adjusted analysis by stage at presentation and histologic grade no significant results 
were found. Same happened with the SES (Table 4), women with lower SES were more 
often under Saint-Gallen than those of higher SES (32.9% vs 27.5%). When adjusting the 
results, (Table 3) these differences disappeared (RRR 0.98, 95% CI 0.62 – 1.54).  
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4. DISCUSSION 
In this study we observed socioeconomic variations in the treatment of early-stage 
breast cancer patients despite universal health insurance coverage in Spain. Women of 
high SES were associated with higher possibilities of being over Saint-Gallen (RRR per 
point 1.14, 95%CI 1.03 – 1.25), and therefore, overcome unnecessary side effects. Those 
of lower SES showed a higher range of under Saint-Gallen therapies; however, such 
disparities disappeared after adjustment by stage at presentation and histologic grade. 
This finding is of great importance given that breast cancer is the most common cancer 
type and the leading cause of cancer death among women worldwide. 
Other studies relating SES with treatment have reported a higher frequency of 
undertreatment in low SES patients (23); they have been predominantly conducted in 
the United States where there is not an equal access health system. Patients from 
Medicaid insurance (24) and those of lower income were less likely to receive guideline 
concordant systemic therapies compared with privately insured women (25,26). 
Therefore, it is plausible that such inequalities could be explainable by financial 
incentives.   
A different study carried on the Netherlands, where there is equal access care system, 
suggested that women of high SES were more prone to undergo aggressive therapeutic 
interventions, even if there was no evidence of benefit and could potentially be harmful 
(27). Patients of low SES were less likely to be overtreated and slightly more likely to be 
undertreated, but this difference was mostly explained by the tendency of higher SES 
women of choosing more aggressive therapies.  Conservative surgery was more often 
performed in women of high SES as higher follow-up proportion was presumed (14). 
Population based studies, also from the Netherlands, have reported higher incidence of 
axillary dissection in patients of high SES (28). In general, there has been reported 
constant tendency to more aggressive therapies  in the majority of  cancers (esophagus, 
colon, breast, etc.) in patients of higher SES (29,30).  
Back to our study, we observed a significant increase of over Saint-Gallen rate in women 
of high SES (RRR 2.12, 95% CI 1.29 – 3.48), and also in those with university studies (RRR 
2.27, 95%CI 1.26 – 4.09). Association of over Saint-Gallen therapies with other SES 
indicators like parents’ SES, DGUR or UVI was not proved significant in any of the 
analysis.  These differences could be explained by a variety of factors.  
Firstly, women of high SES and higher educational level usually play a more proactive 
role in decision making and also, as said before, they tend to prefer more aggressive 
treatments including chemotherapies, aggressive surgeries, etc. Physicians contribution 
should also be noted; in general, not only do the patients play a more proactive role, but 
also the practitioners tend to count more on the patient’s opinion if a higher educational 
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level is supposed. On the other hand, patients of lower SES are also considered less 
educated, so clinicians would have a higher contribution in decision making thus they 
will be more likely to get and in Saint-Gallen therapy. Professionals should be aware of 
this tendency specially in a system that is seeking to provide equal access to health care. 
Other reasons that could explain these deviations from the recommendations could be 
patients’ comorbidities -which have not been considered in this study-; and obviously 
personal preferences and personal situation of the patients, which are not always 
related to the SES itself. In those hospitals where multi-gene molecular assays as 
Mamaprint© were available, clinicians might rely on their results when it comes to 
adjuvant therapy. In any case, SES was not a limiting factor in the decision as all the 
therapies mentioned above are funded by National Health System. 
Possible consequences of our main result would affect both women and the system. 
Under Saint-Gallen women could have been related to higher mortality, however, 
differences in undertreatment ranges were not found. Over Saint-Gallen women, on the 
other side, would not experiment a decrease in mortality rates but, indeed, they would 
suffer more side effects which would suppose direct and indirect costs for both the 
patient and the system. The main goal in breast cancer treatment, and in any treatment 
in general, is always to optimize healing and survival rates without affecting the quality 
of life of the patients.  
Finally, apart from the fact that over Saint-Gallen rate is consistently related to higher 
SES, it is important to notice that such disparities were not found when checking women 
of lower SES. If found, these inequalities would have been devastating for the system, 
as it is presumed to be of equal access. SES indicator DGUR, which is related to the area 
of residence and which could introduce some personal prejudices did not show any 
significant differences. UVI index, which measures the SES level of the area the patient 
is living in, was not proved to have any influence. This partly means that only the 
individual characteristics of the patient have an impact in the final decision, as only her 
individual SES and educational level showed an association.   
 
Strengths and limitations 
Converting recruited cases in the case-control phase on the MCC-Spain into three 
prospective cohorts (colorectal, breast and prostate) is one of the main strengths of this 
study because of its efficiency. We took advantage of the recruitment itself and also 
information and samples collected during the first phase. This led us to the inception of 
the cohort at only the cost of the follow-up. Moreover, the study enrolled women aged 
20-85 years from 12 Spanish provinces, and given the universal coverage of the Spanish 
National Health System, they could provide a representative sample of the population.   
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Some limitations of this study should also be considered. Firstly, part of the information 
regarding SES was self-reported and could be influenced by women’s feelings or beliefs; 
some participants did not report all the data required and others could have 
misreported, which could lead to misclassification bias. However, as women were not 
aware of the main hypotheses of the study, had we introduced some information bias 
we would expect it to be non-differential, which would make more robust the results 
obtained. Secondly, both the Urban Vulnerability Index and the degree of urbanization 
are ecological in nature, which can lead to ecological bias. Finally, as in any cohort, some 
participants have been lost during the follow-up. We have tried to minimize it by 
collecting data from medical records. Nevertheless, due to the small number of patients 
without follow-up, we assume that bias -if exists- would be minimum. 
Summarizing, in this paper we observed that in the Spanish universal health system 
women of higher SES more often received over Saint-Gallen therapies. Being at lower 
SES was not associated with over or under Saint Gallen treatment. Further analyses are 
needed to understand the influence of these differences on the overall survival as well 
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Table 1. Description of the sample (n = 1110) 
 
 
   Saint-Gallen Fulfillment  
Variable Category Total In St Gallen Over St Gallen Under St Gallen p 
Age Mean (SD) 56.1 (12.1) 56.6 (12.6) 52.9 (10.6) 57.6 (11.9) < 0.001 
Post menopause No 389 (35.0) 153 (39.3) 120 (30.9) 116 (29.8) < 0.001 
 Yes 721 (65.0) 340 (47.2) 124 (17.2) 257 (35.6)  
Tumour Size T0 19 (1.7) 7 (36.8) 5 (26.3) 7 (36.8) < 0.001 
 T1 732 (65.9) 350 (47.8) 155 (21.2) 227 (31.0)  
 T2 283 (25.5) 119 (42.1) 77 (27.2) 87 (30.7)  
 T3 15 (1.4) 4 (26.7) 2 (13.3) 9 (60.0)  
 T4 4 (0.4) 1 (25.0) 1 (25.0) 2 (50.0)  
 Tis 44 (4.0) 8 (18.2) 1 (2.3) 35 (79.6)  
 Miss 13 (1.2) 4 (30.8) 3 (23.1) 6 (46.2)  
Node Infiltration N0 739 (66.6) 368 (49.8) 106 (14.3) 265 (35.9) < 0.001 
 N1 365 (32.9) 122 (33.4) 136 (37.3) 107 (29.3)  
 Miss 6 (0.5) 3 (50.0) 2 (33.3) 1 (16.7)  
Metastasis M0 1080 (97.3) 474 (43.9) 242 (22.4) 364 (33.7) 0.05 
 Miss 30 (2.7) 19 (63.3) 2 (6.7) 9 (30.0)  
Qx stage I 637 (57.4) 317 (49.8) 92 (14.4) 228 (35.8) < 0.001 
 II 473 (42.6) 176 (37.2) 152 (32.1) 145 (30.7)  
Oestrogen receptor Negative 150 (13.5) 85 (56.7) 13 (8.7) 52 (34.7) <0.001 
 Positive 959 (86.4) 407 (42.4) 231 (24.1) 321 (33.5)  
 Miss 1 (0.1) 1 (100.0) 0 (0.0) 0 (0.0)  
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Progesterone receptor Negative 245 (22.1) 120 (48.9) 16 (6.5) 109 (44.5) <0.001 
 Positive 860 (77.5) 371 (43.1) 226 (26.3) 263 (30.6)  
 Miss 5 (0.5) 2 (40.0) 2 (40.0) 1 (20.0)  
ErbB2 Negative 927 (83.5) 433 (46.7) 227 (24.5) 267 (28.8) < 0.001 
 Positive 183 (16.5) 60 (32.8) 17 (9.3) 106 (57.9)  
Intrinsic subtype Luminal A 759 (68.4) 339 (44.7) 222 (29.3) 198 (26.1) < 0.001 
 Luminal B 214 (19.3) 75 (35.1) 10 (4.7) 129 (60.3)  
 Her2 51 (4.6) 15 (29.4) 8 (15.7) 28 (54.9)  
 Basal-like 86 (7.8) 64 (74.4) 4 (4.7) 18 (20.9)  
Grade of differentiation I: well differentiated 255 (23.0) 123 (48.2) 74 (29.0) 58 (22.8) < 0.001 
 II: moderately differentiated 336 (30.3) 138 (41.1) 109 (32.4) 89 (26.5)  
 III: bad differentiated 212 (19.1) 117 (55.2) 16 (7.6) 79 (37.3)  
 Miss 307 (27.7) 115 (37.5) 45 (14.7) 147 (47.9)  
Surgery Conservative surgery 861 (77.6) 392 (45.5) 184 (21.4) 285 (33.1) 0.37 
 Mastectomy 249 (22.4) 101 (40.6) 60 (24.1) 88 (35.3)  
Surgical Margins Negative 799 (72.0) 367 (45.9) 178 (22.3) 254 (31.8) 0.19 
 Positive 162 (14.6) 67 (41.4) 38 (23.5) 57 (35.2)  
 Miss 149 (13.4) 59 (39.6) 28 (18.8) 62 (41.6)  
Chemotherapy No 533 (48.0) 285 (53.5) 2 (0.4) 246 (46.2) < 0.001 
 Yes 577 (52.0) 208 (36.1) 242 (41.9) 127 (22.0)  
Endocrine No 363 (32.7) 79 (21.8) 13 (3.6) 271 (74.7) < 0.001 
 Yes 747 (67.3) 414 (55.4) 231 (30.9) 102 (13.7)  
Immunotherapy No 1003 (90.4) 430 (42.9) 223 (22.2) 350 (34.9) 0.004 
 Yes 107 (9.6) 63 (58.9) 21 (19.6) 23 (21.5)  
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Table 2. Association between SES indicators and Saint-Gallen Fulfillment 
   Saint-Gallen Fulfillment  
   In St Gallen Over St Gallen Under St Gallen  
SES indicator Category Total    p 
Education Less than primary 161 (14.5) 75 (46.6) 25 (15.5) 61 (37.9) 0.06 
 Primary 344 (31.0) 166 (48.3) 70 (20.4) 108 (31.4)  
 Secondary 396(35.7) 165 (41.7) 90 (22.7) 141 (35.6)  
 University 209 (18.8) 87 (41.6) 59 (28.2) 63 (30.1)  
Companion Ed. Less than primary 108 (11.6) 49 (45.4) 20 (18.5) 39 (36.1) 0.36 
 Primary 307 (32.9) 150 (48.9) 63 (20.5) 94 (30.6)  
 Secondary 301 (32.3) 119 (39.5) 67 (22.3) 115 (38.2)  
 University 216 (23.2) 96 (44.4) 49 (22.7) 71 (32.9)  
SES 0 52 (4.7) 23 (44.2) 8 (15.4) 21 (40.4) 0.06 
 1 142 (12.8) 71 (50.0) 21 (14.8) 50 (35.2)  
 2 168 (15.1) 82 (48.8) 37 (22.0) 49 (29.2)  
 3 202 (18.2) 83 (41.1) 51 (25.3) 68 (33.7)  
 4 203 (18.4) 85 (41.9) 40 (19.7) 78 (38.4)  
 5 186 (16.8) 82 (44.1) 37 (19.9) 67 (36.0)  
 6 148 (13.3) 62 (41.9) 48 (32.4) 38 (25.7)  
 7 9 (0.8) 5 (55.6) 2 (22.2) 2 (22.2)  
Summary SES Mean (SD) 3.40 (1.76) 3.33 (1.79) 3.66 (1.74) 3.33 (1.73) 0.0001 
SES score Low 609 (54.9) 163 (48.8) 61 (18.3) 110 (32.9) 0.02 
 Medium 334 (30.1) 259 (42.5) 133 (21.8) 217 (35.6)  
 High 167 (15.0) 71 (42.5) 50 (29.9) 46 (27.5)  
SES parents Low 365 (32.9) 166 (45.5) 71 (19.5) 128 (35.1) 0.59 
 Medium 714 (64.3) 312 (43.7) 168 (23.5) 234 (32.8)  
 High 29 (2.6) 14 (48.3) 5 (17.2) 10 (34.5)  
DGUR Dense 625 (74.5) 284 (45.4) 138 (22.1) 203 (32.5) 0.75 
 Intermediate 149 (17.8) 64 (43.0) 30 (20.1) 55 (36.9)  
 Thinly 65 (7.7) 33 (50.8) 12 (18.5) 20 (30.8)  
UVI Mean (SD) 0.50 (0.14) 0.50 (0.14) 0.51 (0.15) 0.49 (0.13) 0.03 
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  Saint Gallen-Fulfillment 
  Over St Gallen Under St Gallen 
SES indicator Category RRR (95% CI) p RRR (95% CI) p 
Education Less than primary 1 (ref.) - 1 (ref.) - 
 Primary 1.30 (0.75 – 2.26) 0.35 0.80 (0.52 – 1.22) 0.30 
 Secondary 1.54 (0.90 – 2.65) 0.12 1.01 (0.67 – 1.52) 0.97 
 University 2.27 (1.26 – 4.09) 0.006 0.93 (0.58 – 1.50) 0.77 
Companion Ed. Less than primary 1 (ref.) - 1 (ref.) - 
 Primary 1.04 (0.55 – 1.96) 0.90 0.80 (0.48 – 1.31) 0.48 
 Secondary 1.44 (0.76 – 2.71) 0.26 1.18 (0.72 – 1.95) 0.51 
 University 1.36 (0.70 – 2.62) 0.37 0.93 (0.55 – 1.58) 0.80 
SES Per point 1.14 (1.03 – 1.25) 0.008 1.00 (0.93 – 1.08) 0.99 
SES score Low 1 (ref.) - 1 (ref.) - 
 Medium  1.47 (1.00 – 2.15) 0.05 1.16 (0.85 – 1.58) 0.35 
 High 2.12 (1.29 – 3.48) 0.003 0.98 (0.62 – 1.54) 0.92 
SES parents Low 1 (ref.) - 1 (ref.) - 
 Medium 1.24 (0.87 – 1.76) 0.24 0.95 (0.71 – 1.27) 0.73 
 High 0.79 (0.27 – 2.38) 0.68 1.02 (0.43 – 2.40) 0.97 
DGUR Dense 1 (ref.) - 1 (ref.) - 
 Intermediate 1.12 (0.66 – 1.90) 0.68 0.89 (0.58 – 1.38) 0.61 
 Thinly 0.73 (0.35 – 1.49) 0.39 0.81 (0.44 – 1.47) 0.48 
UVI Per point 1.26 (0.33 – 4.77) 0.73 0.82 (0.26 – 2.56) 0.73 
RRR: relative risk ratio 
Education: educational level of the patients 
Companion Ed.: educational level of the patients’ 
companions.  
 
SES: socio-economic status 
SES score: simplified socio-economic status 
DGUR: degree of urbanization 
UVI: urban vulnerability index 
 
